Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tuftsin - unimportant or forgotten?

S W Mikulski, D D Von Hoff, M Rozencweig

    The New England Journal of Medicine
    |February 24, 1977
    PubMed
    Summary

    No abstract available in PubMed .

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
    Same author

    Positron emission tomography (PET) as a predictive measure in patients with metastatic pancreatic cancer and normal CA19-9 levels at baseline.

    Annals of oncology : official journal of the European Society for Medical Oncology·2016
    Same author

    Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas.

    Annals of oncology : official journal of the European Society for Medical Oncology·2016
    Same author

    CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.

    Annals of oncology : official journal of the European Society for Medical Oncology·2016
    Same author

    Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001).

    Cancer chemotherapy and pharmacology·2014
    Same author

    Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies.

    European journal of cancer (Oxford, England : 1990)·2012
    Same journal

    Ebola at 50 - Lessons for Outbreak Response and Preparedness.

    The New England journal of medicine·2026
    Same journal

    Ianalumab plus Eltrombopag in Immune Thrombocytopenia. Reply.

    The New England journal of medicine·2026
    Same journal

    Ianalumab plus Eltrombopag in Immune Thrombocytopenia.

    The New England journal of medicine·2026
    Same journal

    Hypertension Control in Low-Income Patients. Reply.

    The New England journal of medicine·2026
    Same journal

    Hypertension Control in Low-Income Patients.

    The New England journal of medicine·2026
    Same journal

    Hypertension Control in Low-Income Patients.

    The New England journal of medicine·2026
    See all related articles